SCHEMBL3635892

SCHEMBL3635892

COc1cccc(-c2cocn2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
NOTUM Q6P988 2/20 0.50
SCN9A Q15858 2/20 0.49
CYP19A1 P11511 1/20 0.47
KDM4E B2RXH2 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ATP4A P20648 1/20 0.45
ATP4B P51164 1/20 0.45
TOP1 P11387 1/20 0.45
PKM P14618 1/20 0.45
GRM5 P41594 1/20 0.45
KDM1A O60341 1/20 0.45
MAP4K4 O95819 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8007795 0.86 ABL1 (0.54) DYRK1ASCN9AKMT2ANPC1RAB9A
SCHEMBL1186835 0.79 ENPP3 (0.50) DYRK1ACLK4KDM4EKMT2ANPC1
SCHEMBL10263248 0.77 SCN9A (0.53) NOTUMSCN9AKDM4ENPC1RAB9A
SCHEMBL13458067 0.77 DYRK1A (0.61) DYRK1ACLK4CYP19A1NPC1RAB9A
SCHEMBL16159336 0.76 SCN9A (0.55) SCN9ACYP19A1SMN1; SMN2CYP1A2CYP3A4
SCHEMBL14564377 0.75 SCN9A (0.62) SCN9A
SCHEMBL6163665 0.75 GABRG2 (0.51) SCN9AKDM4ENPC1RAB9AGRM5
SCHEMBL29470234 0.74 DYRK1A (0.58) DYRK1ACLK4CYP19A1KDM4ENPC1
SCHEMBL3630297 0.74 DYRK1A (0.58) DYRK1ACLK4CYP19A1KDM4ENPC1
SCHEMBL17794305 0.74 SCN9A (0.53) SCN9AKDM4EKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155718-A2 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
WO-2008148710-A2 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed
US-20080306116-A1 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed
WO-2008129129-A1 HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS KUOPION YLIOPISTO (FI) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306116-A1 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES SSTR5, NPY5R, SSTR3 DYRK1A 879/4885CLK4 3080/4885NOTUM 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.